Travere Therapeutics (TVTX) shares soared 11.6% in the last trading session to close at $15.23. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 37.5% gain over the past four weeks. Last month, the FDA granted full approval to the company's marketed product, Filspari (sparsentan), an oral non-immunosuppressive drug, for treating primary IgA nephropathy (IgAN) in adults who stand at high/low risk of disease progression. The approva ...

NEW YORK, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Travere Therapeutics, Inc. ("Travere" or "the Company") (NASDAQ: TVTX). Investors who purchased Travere securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TVTX. Investigation Details On September 26, 2024, Travere issued a press release "announc[ing] a voluntary pause of ...

Travere Therapeutics, Inc. (NASDAQ: TVTX ) specializes in treatments for rare kidney and metabolic diseases. TVTX's portfolio includes FDA-approved drugs like Filspari [Sparsentan] for IgA Nephropathy [IgAN] and Thiola [Tiopronin] for cystinuria. Filspari received full FDA approval in September 2024, expanding its label and expanding patient access. However, its Phase My name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Naciona ...

SAN DIEGO, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced a voluntary pause of enrollment in the Phase 3 HARMONY Study evaluating pegtibatinase for the treatment of classical homocystinuria (HCU). The voluntary enrollment pause enables the Company to work to address necessary process improvements in manufacturing scale-up to support commercial scale manufacturing as well as full enrollment in the HARMONY Study. Patients currently enrolled in pegtibatinase studi ...

Travere Therapeutics (TVTX) shares rallied 5.9% in the last trading session to close at $14.27. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 55.3% gain over the past four weeks. The company markets Filspari (sparsentan), an oral non-immunosuppressive drug approved for treating IgA nephropathy (IgAN), a rare kidney disease. Filspari has seen strong market demand, generating $47 million in sales in the first ...

Travere Therapeutics (TVTX) announced that the FDA granted full approval to its oral nonimmunosuppressive drug Filspari (sparsentan) in IgA nephropathy (IgAN) indication, a rare progressive kidney disease. Following this decision, Filspari is approved for slowing kidney function decline in adults with primary IgAN who are at risk of disease progression. The FDA's decision also makes Filspari the only nonimmunosuppressive medication in the IgAN space. Filspari was initially granted accelerated approval in Fe ...

FDA approves expanded indication making FILSPARI available to patients with IgA nephropathy (IgAN) at risk of progression; updated label includes data showing long-term durable benefit on proteinuria and kidney function preservation that accrued over two years Conversion to full approval based on results from the PROTECT Study, where FILSPARI delivered superior long-term kidney function preservation compared to the active comparator irbesartan in the only Phase 3 headto-head trial conducted in IgAN As an or ...

Chris Ryan/OJO Images via Getty Images Investment Overview - Background To Upcoming PDUFA - Failed Confirmatory Study Hammers Share Price The last time I covered Travere Therapeutics (NASDAQ:TVTX) it was September 22, 2023, and the San Diego-based biotech's stock price was in free-fall. Earlier that day, the company shared data from a Phase 3 clinical study of its lead asset Filspari (sparsentan), showing that the drug had failed to meet a key primary endpoint, unable to demonstrate a statistically signific ...

SAN DIEGO, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the Company will present two posters in classical homocystinuria (HCU) at the Society for the Study of Inborn Errors of Metabolism (SSIEM) annual symposium in Porto, Portugal, September 3-6, 2024. At SSIEM, the Company will present the trial designs of the pivotal Phase 3 HARMONY Study and ENSEMBLE long-term extension study of pegtibatinase, a novel investigational enzyme replacement therapy for the ...

SAN DIEGO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that company management will present in the following upcoming investor conferences in August: 2024 Wedbush PacGrow Healthcare Conference Tuesday, August 13, 2024, at 2:30 p.m. ET Canaccord Genuity 44th Annual Growth Conference Wednesday, August 14, 2024, at 12:30 p.m. ET A live webcast of the Canaccord Genuity 44th Annual Growth Conference presentation will be accessible on the Investor page of Travere's ...